title: Eplerenone attenuates cardiac dysfunction and oxidative stress in β-receptor stimulated myocardial infarcted rats.
abstract: Eplerenone is a competitive antagonist of the aldosterone receptor with an additional PI3K-Akt activity. The existing cram has been intended to explore, whether eplerenone treatment attenuates the expansion of myocardial infarction in isoproterenol treated rats by restoring hemodynamic, biochemical, and histopathological changes. Isoproterenol induced cardiotoxicity was evidenced by marked ST elevation, decrease in systolic, diastolic, mean arterial pressures. Maximal positive rate of developed left ventricular pressure (+LVdP/dt max, a indicator of myocardial contraction), maximal negative rate of developed left ventricular pressure (-LVdP/dt max, a meter of myocardial relaxation) and an increase in left ventricular end-diastolic pressure (LVEDP, a marker of pre-load) were also shown. In addition, a significant reduction in activities of myocardial creatine kinase-MB isoenzyme, lactate dehydrogenase, superoxide dismutase, catalase, and reduced glutathione level along with increase in malondialdehyde content were observed. Oral pre-treatment with eplerenone (50, 100 and 150 mg/kg) daily for a period of 14 days, constructively modulated the studied parameters in isoproterenol-induced myocardial injury. The protective role of eplerenone on isoproterenolinduced myocardial damage was further confirmed by histopathological examinations. Eplerenone at doses of 100 mg/kg and 150 mg/kg produced more pronounced protective effects than 50 mg/kg body weight. Together, our study provides evidence for protective effects of eplerenone on myocardium in experimentally induced myocardial infarction.
authors.affiliation: Cardiovascular Pharmacology Division, Department of Pharmacology, R. C. Patel Institute of Pharmaceutical Education and Research Shirpur-Dist-Dhule, Maharashtra, India.
authors.forename: Navya M
authors.initials: NM
authors.lastname: Reddy
authors.affiliation: Cardiovascular Pharmacology Division, Department of Pharmacology, R. C. Patel Institute of Pharmaceutical Education and Research Shirpur-Dist-Dhule, Maharashtra, India.
authors.forename: Umesh B
authors.initials: UB
authors.lastname: Mahajan
authors.affiliation: Cardiovascular Pharmacology Division, Department of Pharmacology, R. C. Patel Institute of Pharmaceutical Education and Research Shirpur-Dist-Dhule, Maharashtra, India.
authors.forename: Chandragouda R
authors.initials: CR
authors.lastname: Patil
authors.affiliation: Department of Pharmaceutics and Quality Assurance, R. C. Patel Institute of Pharmaceutical Education and Research Shirpur-Dist-Dhule, Maharashtra, India.
authors.forename: Yogeeta O
authors.initials: YO
authors.lastname: Agrawal
authors.affiliation: Department of Pharmacology and Therapeutics College of Medicine and Health Sciences, United Arab Emirates University Al-Ain, United Arab Emirates.
authors.forename: Shreesh
authors.initials: S
authors.lastname: Ojha
authors.affiliation: Cardiovascular Pharmacology Division, Department of Pharmacology, R. C. Patel Institute of Pharmaceutical Education and Research Shirpur-Dist-Dhule, Maharashtra, India.
authors.forename: Sameer N
authors.initials: SN
authors.lastname: Goyal
keywords: Eplerenone; LVEDP; ST elevation; isoproterenol; myocardial infarction